What is iVEAcare?
iVEAcare operates at the intersection of advanced engineering and clinical medicine, specializing in the development of innovative neuromodulation therapies. The company is dedicated to solving unmet clinical needs through sophisticated technological interventions that modulate neural activity to improve patient outcomes. By focusing on high-impact therapeutic areas, iVEAcare distinguishes itself as a key player in the evolving MedTech landscape, where precision medicine and device-based treatments are increasingly prioritized over traditional pharmacological approaches. Its market position is defined by a commitment to rigorous scientific validation and the pursuit of scalable solutions that can be integrated into standard clinical workflows.
How much funding has iVEAcare raised?
iVEAcare has raised a total of $27.5M across 1 funding round:
Series A
$27.5M
Series A (2024): $27.5M with participation from Treo Ventures, Vensana Capital Management, and Hatteras Venture Partners
Key Investors in iVEAcare
Treo Ventures
Founded in 2018, Treo Ventures is a capital fund created to focus on medical device and digital health innovation targeting large unmet healthcare needs.
Vensana Capital Management
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs to drive innovation in healthcare through medical technology.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors.
What's next for iVEAcare?
Looking ahead, the infusion of capital will likely be directed toward expanding clinical trial operations and enhancing the company's intellectual property portfolio. As iVEAcare moves deeper into its growth phase, the focus will shift toward regulatory milestones and the establishment of commercialization pathways. The strategic backing from specialized healthcare investors suggests a long-term commitment to scaling the technology, with potential future efforts centered on market penetration and the development of next-generation neuromodulation platforms. The company is now tasked with translating its technical advancements into tangible clinical benefits, a process that will be closely monitored by its syndicate of venture partners.
See full iVEAcare company page
